Hospital
Hca Healthone LLC
Hca Healthone LLC was paid $30.58M by Medicaid between Jan 2018 and Dec 2024, across 108 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoHCA HEALTHONE LLC
THORNTON, CO 80229
THORNTON, CO 80229
33aNPI1821042979assigned 05/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.58M
24GClaims819,016
24DCodes billed108
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#5 of 51
Median peer was paid$1.24M
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 111,097 | $4.43M | |
| 2019 | 108,785 | $4.38M | |
| 2020 | 100,912 | $3.75M | |
| 2021 | 144,544 | $3.89M | |
| 2022 | 123,227 | $4.77M | |
| 2023 | 132,386 | $5.47M | |
| 2024incomplete | 98,065 | $3.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 83,459 | 75,566 | $10.26M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 89,678 | 79,498 | $9.83M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 12,384 | 10,974 | $3.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 7,346 | 6,451 | $1.29M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 10,187 | 9,377 | $1.10M |
| 80053 | Comprehensive metabolic panel | 3.3% | 67,276 | 59,505 | $1.02M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 4,808 | 4,177 | $888K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 4,304 | 3,728 | $552K |
| 84484 | 1.5% | 27,458 | 20,363 | $451K | |
| 80320 | 1.1% | 3,728 | 2,962 | $341K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 16,902 | 14,813 | $324K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,095 | 3,482 | $215K |
96 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,912 | $170K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 453 | $79K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 630 | $70K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 59,837 | $66K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,536 | $66K |
| 29827 | <1% | 12 | $62K | |
| 83605 | <1% | 3,466 | $41K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 271 | $33K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 373 | $32K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 133 | $31K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 742 | $30K |
| 85027 | <1% | 90,557 | $27K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38,319 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 36,560 | $21K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 244 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 123 | $20K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 100 | $14K |
| 80076 | <1% | 886 | $13K | |
| 84703 | <1% | 21,049 | $11K | |
| 83690 | <1% | 28,841 | $8K | |
| 93880 | <1% | 66 | $8K | |
| G0378 | Hospital observation service, per hour | <1% | 339 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 696 | $8K |
| A0425 | Ground mileage, per statute mile | <1% | 279 | $7K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 63 | $7K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 155 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,494 | $5K |
| 87634 | <1% | 74 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 25,193 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,523 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 29,470 | $4K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 18 | $4K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 13 | $3K |
| 70496 | <1% | 29 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,471 | $3K |
| 81001 | <1% | 10,014 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,250 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,853 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 428 | $3K |
| 87430 | <1% | 1,719 | $3K | |
| 85379 | <1% | 330 | $2K | |
| 81025 | <1% | 3,683 | $2K | |
| 87081 | <1% | 1,115 | $2K | |
| 81003 | <1% | 7,906 | $1K | |
| 93975 | <1% | 12 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 805 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 28,047 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,950 | $832.92 |
| 73610 | <1% | 31 | $774.82 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 20,631 | $745.72 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,312 | $587.13 |
| 70498 | <1% | 13 | $549.33 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 898 | $464.00 |
| 83880 | <1% | 80 | $365.64 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,297 | $288.03 |
| 90715 | <1% | 15 | $261.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 48 | $193.79 |
| 83735 | <1% | 350 | $109.81 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 790 | $55.18 |
| 82077 | <1% | 4,500 | $41.04 | |
| 73130 | <1% | 14 | $21.46 | |
| 85610 | <1% | 2,121 | $18.30 | |
| 82805 | <1% | 28 | $9.29 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,490 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 340 | $0.00 |
| 85730 | 0% | 266 | $0.00 | |
| 82550 | 0% | 46 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 488 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 60 | $0.00 |
| 86901 | 0% | 83 | $0.00 | |
| 64415 | 0% | 28 | $0.00 | |
| 70486 | 0% | 12 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 55 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 369 | $0.00 |
| 87088 | 0% | 36 | $0.00 | |
| 29826 | 0% | 12 | $0.00 | |
| 81015 | 0% | 37 | $0.00 | |
| 96376 | 0% | 59 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 15 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 14 | $0.00 |
| 86850 | 0% | 12 | $0.00 | |
| 86140 | 0% | 17 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 12 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,202 | $0.00 |
| 82248 | 0% | 1,539 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,344 | $0.00 |
| 87400 | 0% | 110 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 121 | $0.00 |
| 86900 | 0% | 83 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 289 | $0.00 |
| 74018 | 0% | 12 | $0.00 | |
| 29823 | 0% | 13 | $0.00 | |
| 73562 | 0% | 16 | $0.00 | |
| 73630 | 0% | 16 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESSLER, HAYDEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hca-Healthone, LLC | Aurora, CO | $6.60M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.